Roche lets Broad try new tricks with old, failed drugs

If at first you don't succeed, let someone else try again. Roche ($RHHBY) is handing over 300 failed drugs to the Broad Institute for screening. New testing methods and screening tools might uncover new uses for the compounds. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.